These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

940 related articles for article (PubMed ID: 21119734)

  • 1. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.
    Rupprecht R; Papadopoulos V; Rammes G; Baghai TC; Fan J; Akula N; Groyer G; Adams D; Schumacher M
    Nat Rev Drug Discov; 2010 Dec; 9(12):971-88. PubMed ID: 21119734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The translocator protein (18kDa) and its role in neuropsychiatric disorders.
    Barichello T; Simões LR; Collodel A; Giridharan VV; Dal-Pizzol F; Macedo D; Quevedo J
    Neurosci Biobehav Rev; 2017 Dec; 83():183-199. PubMed ID: 29054730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocator protein (TSPO) and neurosteroids: implications in psychiatric disorders.
    Da Pozzo E; Costa B; Martini C
    Curr Mol Med; 2012 May; 12(4):426-42. PubMed ID: 22348611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders.
    Milenkovic VM; Rupprecht R; Wetzel CH
    Mini Rev Med Chem; 2015; 15(5):366-72. PubMed ID: 25807946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection.
    Da Pozzo E; Giacomelli C; Barresi E; Costa B; Taliani S; Passetti Fda S; Martini C
    Biochem Soc Trans; 2015 Aug; 43(4):559-65. PubMed ID: 26551693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders.
    Nothdurfter C; Baghai TC; Schüle C; Rupprecht R
    Eur Arch Psychiatry Clin Neurosci; 2012 Nov; 262 Suppl 2():S107-12. PubMed ID: 22923187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translocator protein (TSPO): the new story of the old protein in neuroinflammation.
    Lee Y; Park Y; Nam H; Lee JW; Yu SW
    BMB Rep; 2020 Jan; 53(1):20-27. PubMed ID: 31818362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving understanding of translocator protein 18 kDa (TSPO).
    Li F; Liu J; Garavito RM; Ferguson-Miller S
    Pharmacol Res; 2015 Sep; 99():404-9. PubMed ID: 25882248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant-like effects of translocator protein (18 kDa) ligand ZBD-2 in mouse models of postpartum depression.
    Li XB; Liu A; Yang L; Zhang K; Wu YM; Zhao MG; Liu SB
    Mol Brain; 2018 Mar; 11(1):12. PubMed ID: 29506545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells.
    Bader S; Wolf L; Milenkovic VM; Gruber M; Nothdurfter C; Rupprecht R; Wetzel CH
    Psychoneuroendocrinology; 2019 Aug; 106():65-76. PubMed ID: 30954920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases.
    Arbo BD; Benetti F; Garcia-Segura LM; Ribeiro MF
    J Steroid Biochem Mol Biol; 2015 Nov; 154():68-74. PubMed ID: 26200949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocator protein as a promising target for novel anxiolytics.
    Costa B; Da Pozzo E; Martini C
    Curr Top Med Chem; 2012; 12(4):270-85. PubMed ID: 22204481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.
    Taliani S; Pugliesi I; Da Settimo F
    Curr Top Med Chem; 2011; 11(7):860-86. PubMed ID: 21291396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair.
    Chen MK; Guilarte TR
    Pharmacol Ther; 2008 Apr; 118(1):1-17. PubMed ID: 18374421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward.
    Guilarte TR
    Pharmacol Ther; 2019 Feb; 194():44-58. PubMed ID: 30189290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ligands of Translocator Protein: Design and Biological Properties.
    Mokrov GV; Deeva OA; Gudasheva TA
    Curr Pharm Des; 2021; 27(2):217-237. PubMed ID: 32881658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation and psychiatric disorders: Relevance of C1q, translocator protein (18 kDa) (TSPO), and neurosteroids.
    Rupprecht R; Rupprecht C; Di Benedetto B; Rammes G
    World J Biol Psychiatry; 2022; 23(4):257-263. PubMed ID: 34320915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog.
    Filiou MD; Banati RB; Graeber MB
    CNS Neurol Disord Drug Targets; 2017; 16(9):990-999. PubMed ID: 28982340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies.
    Grimm A; Lejri I; Hallé F; Schmitt M; Götz J; Bihel F; Eckert A
    J Neuroendocrinol; 2020 Jan; 32(1):e12796. PubMed ID: 31536662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mitochondrial translocator protein (TSPO): a key multifunctional molecule in the nervous system.
    El Chemali L; Akwa Y; Massaad-Massade L
    Biochem J; 2022 Jul; 479(13):1455-1466. PubMed ID: 35819398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.